504 related articles for article (PubMed ID: 30238151)
1. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
[TBL] [Abstract][Full Text] [Related]
2. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
4. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
[TBL] [Abstract][Full Text] [Related]
5. Rare genetic variant in the CFB gene presenting as atypical hemolytic uremic syndrome and immune complex diffuse membranoproliferative glomerulonephritis, with crescents, successfully treated with eculizumab.
Alfakeeh K; Azar M; Alfadhel M; Abdullah AM; Aloudah N; Alsaad KO
Pediatr Nephrol; 2017 May; 32(5):885-891. PubMed ID: 28210841
[TBL] [Abstract][Full Text] [Related]
6. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children.
Okuda Y; Ishikura K; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Fukuzawa R; Ogata K; Honda M
Nephrology (Carlton); 2015 Apr; 20(4):286-92. PubMed ID: 25524631
[TBL] [Abstract][Full Text] [Related]
7. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features of C3 glomerulopathy in children: a single-center experience.
Drake KA; Ellington N; Gattineni J; Torrealba JR; Hendricks AR
Pediatr Nephrol; 2020 Jan; 35(1):153-162. PubMed ID: 31667615
[TBL] [Abstract][Full Text] [Related]
9. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
10. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
[TBL] [Abstract][Full Text] [Related]
11. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
Le Quintrec M; Lapeyraque AL; Lionet A; Sellier-Leclerc AL; Delmas Y; Baudouin V; Daugas E; Decramer S; Tricot L; Cailliez M; Dubot P; Servais A; Mourey-Epron C; Pourcine F; Loirat C; Frémeaux-Bacchi V; Fakhouri F
Am J Kidney Dis; 2018 Jul; 72(1):84-92. PubMed ID: 29429752
[TBL] [Abstract][Full Text] [Related]
12. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
Front Immunol; 2021; 12():715704. PubMed ID: 34456924
[TBL] [Abstract][Full Text] [Related]
13. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment.
Noris M; Daina E; Remuzzi G
Nephrol Dial Transplant; 2023 Feb; 38(2):283-290. PubMed ID: 34596686
[TBL] [Abstract][Full Text] [Related]
14. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
[TBL] [Abstract][Full Text] [Related]
15. C3 glomerulopathy and eculizumab: a report on four paediatric cases.
Lebreton C; Bacchetta J; Dijoud F; Bessenay L; Fremeaux-Bacchi V; Sellier-Leclerc AL
Pediatr Nephrol; 2017 Jun; 32(6):1023-1028. PubMed ID: 28236143
[TBL] [Abstract][Full Text] [Related]
16. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.
Ravindran A; Fervenza FC; Smith RJH; Sethi S
Kidney Int; 2018 Jul; 94(1):178-186. PubMed ID: 29729982
[TBL] [Abstract][Full Text] [Related]
17. C3G and Ig-MPGN-treatment standard.
Noris M; Remuzzi G
Nephrol Dial Transplant; 2024 Jan; 39(2):202-214. PubMed ID: 37604793
[TBL] [Abstract][Full Text] [Related]
18. FHR-5 Serum Levels and
Garam N; Cserhalmi M; Prohászka Z; Szilágyi Á; Veszeli N; Szabó E; Uzonyi B; Iliás A; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Rysava R; Reiterova J; Saraga M; Seeman T; Zieg J; Sládková E; Stajic N; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Józsi M; Csuka D
Front Immunol; 2021; 12():720183. PubMed ID: 34566977
[TBL] [Abstract][Full Text] [Related]
19. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis.
Gupta N; Wakefield DN; Clapp WL; Garin EH
Nefrologia; 2017; 37(1):78-86. PubMed ID: 27595516
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series.
Avasare RS; Canetta PA; Bomback AS; Marasa M; Caliskan Y; Ozluk Y; Li Y; Gharavi AG; Appel GB
Clin J Am Soc Nephrol; 2018 Mar; 13(3):406-413. PubMed ID: 29326307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
